Clinical Trial Update: Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing whether risedronate can prevent chemotherapy-induced bone loss in premenopausal women treated for primary breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Osteoporosis

Drugs mentioned

• risedronate (risedronate)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Breast Cancer, Osteoporosis | Phase 3 | Status: COMPLETED